Bioimpedance Analyzers Market

The global bioimpedance analyzers market in terms of revenue was estimated to be worth $564 million in 2023 and is poised to reach $927 million by 2028, growing at a CAGR of 10.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals and fitness clubs, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.

Attractive Opportunities in the Bioimpedance Analyzers Market

To know about the assumptions considered for the study, Request for Free Sample Report

Bioimpedance Analyzers Market Dynamics

DRIVER: Increasing prevalence of lifestyle diseases

The rising prevalence of various lifestyle diseases, such as obesity, high blood pressure, and diabetes, is probably due to unhealthy lifestyles, such as sedentary work environments, eating more junk food, and increased mobility automation.

According to the World Obesity Atlas 2023, over 4 billion people may be affected by 2035, compared with over 2.6 billion in 2020. Thus, there is an increase from 38% of the world’s population in 2020 to over 50% by 2035. The prevalence of obesity (BMI ≥30kg/m²) alone is anticipated to rise from 14% to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.

RESTRAINT: High cost of analyzers

The smaller healthcare facilities, clinics, and resource-constrained regions will get limited by the high cost of analyzers. Depending on the features, capabilities, and frequency, bioimpedance analyzers can range in pricing. For some healthcare facilities, fitness centers, and research institutions, especially smaller or resource-constrained organizations, the cost of acquiring and maintaining these devices can be a significant barrier. The price of bioimpedance analyzers can range from USD 2,000- USD 30,000.

OPPORTUNITY: Integration with wearable devices

Wearable devices, such as fitness trackers or smartwatches, to monitor body composition and hydration status could be integrated with bioimpedance analyzers. This integration will allow for real-time data collection and analysis, which will enable individuals to track their health parameters throughout the day and make informed decisions about their lifestyle and behavior.

Although bioimpedance monitoring is not a new concept, wearable bioimpedance monitoring for chronic conditions is a relatively new field [Source: Journal of Medical Internet Research (JMIR)].

CHALLENGE: Inconsistency in the accuracy of different bioimpedance analyzers

Although valuable information about body composition and hydration status can be obtained with bioimpedance analyzers, their accuracy may vary depending on age, gender, body type, and hydration level. They may not be as accurate as gold standard methods like DEXA or hydrostatic weighing in some cases. The number represents an estimate of the total body fat percentage, even though one gets an accurate reading on a bioimpedance scale. Most of the scales also cannot tell where fat is located in the body. Even though many factors can affect reading accuracy, a regular BIA scale can show changes in body fat over time. However, the obtained number may not be accurate but can still track changes to the body composition. This limitation can deter healthcare professionals and researchers who require exact measurements.

BIOIMPEDANCE ANALYZERS ECOSYSTEM

Prominent companies in this market include well-established, financially stable manufacturers of bioimpedance analyzers. These companies have been operating in the market for several years and possess diversified state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include OMRON Corporation (Japan), Tanita Corporation (Japan), InBody (South Korea), RJL Systems (US), and Seca GmbH & Co. KG (Germany).

In 2022, multi-frequency bioimpedance analyzers segment to observe the highest growth rate of the bioimpedance analyzers industry, by product.

Based on product, the bioimpedance analyzers market is classified into multi-frequency, single-frequency, and dual-frequency bioimpedance analyzers. In 2022, the multi-frequency bioimpedance analyzers segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share can be attributed to features like advanced tissue differentiation and integration with other technologies.

“In 2022, segmental body measurement segment to dominate the bioimpedance analyzers industry, by application.

Based on application, the bioimpedance analyzers market is segmented into segmental body measurement and whole-body measurement. The segmental body measurement segment accounted for the largest share of the market in 2022. Also, this segment is estimated to witness the highest growth during the forecast period. The large share is due to tracking changes in specific body segments by athletes and monitoring the effectiveness of the training programs.

In 2022, North America to dominate in bioimpedance analyzers industry.

The global bioimpedance analyzers market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate during the forecast period, primarily due to the high promotion of healthy lifestyles, sedentary work life, and large population consuming junk food.

To know about the assumptions considered for the study, download the pdf brochure

The bioimpedance analyzers market is dominated by players such as OMRON Corporation (Japan), Tanita Corporation (Japan), InBody (South Korea), RJL Systems (US), and Seca GmbH (Germany)

Scope of the Bioimpedance Analyzers Industry

This research report categorizes the bioimpedance analyzers market to forecast revenue and analyze trends in each of the following submarkets:

Recent Developments of Bioimpedance Analyzers Industry

• In 2023, Bodystat Ltd. (UK) launched the Multiscan 5000, which incorporates the latest state-of-the-art bioelectrical impedance spectroscopy (BIS) technology based on direct digital synthesis, digital signal processing, and active shielding technology.
• In 2023, InBody Co., Ltd. (South Korea) announced it would supply the US Marine Corps with body composition analysis devices. The US Marine Corps announced refinements in its body composition assessment methods using the InBody 770 analyzer.
• In 2022, InBody Co., Ltd. (South Korea) partnered with iLoveKickboxing (US). The partnership offered iLoveKickboxing members access to high-quality data about their body fat percentage, muscle mass, and other biometrics. It enabled them to monitor changes over time via the InBody App.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst